Prevention of Measles, Mumps and Rubella
Combined vaccine Vactrivir intended for prevention of measles, mumps and rubella was developed by scientists at the National Immunobiological Company (a company of Rostech State Corporation) in cooperation with colleagues from the daughter company NPO Microgen.
The project concerns a locally manufactured live combination vaccine. Full spectrum of preclinical trials and phase I clinical trials on adult volunteers have been successfully completed. Currently clinical trial of reactogenicity, safety and immunogenicity of the vaccine is ongoing. It is to be completed in quarter three, 2017. 50 6-year-old children have already completed the study. The vaccine is expected to be approved at the end of 2018. If the situation evolves as planned, after marketing authorization Vactivir will be used within the National Vaccination Schedule. The new vaccine will significantly improve the quality of life of mothers and children, as it will require only one injection, instead of three to provide protection against mumps, measles and rubella.